HealthMore in Health→
Induced pluripotent stem cells move toward standardized medicine
Key Takeaways
- A Nature Medicine review says iPSC science has matured into a clinical platform with trials and early approvals underway.
- The field’s progress rests on advances in nonintegrating reprogramming, differentiation, tissue engineering and genome editing.
- Researchers still face major barriers in biological variability, manufacturing complexity and long-term safety surveillance.
- The authors argue automation and AI could help turn iPSC workflows into scalable, standardized biological medicine systems.
DE
DT Editorial Team··via nature.com
